65619-20-7

Basic information

• Product Name: 4-(dimethylamino)-4-phenylcyclohexan-1-one
• Synonyms: 4-(dimethylamino)-4-phenylcyclohexan-1-one;4-(Dimethylamino)-4-phenylcyclohexanone
• CAS NO: 65619-20-7
• Molecular Formula: C₁₄H₁₉NO
• Molecular Weight: 217.30676
• Mol File: 65619-20-7.mol

Chemical Properties

• Melting Point: 98-99.5 °C(Solv: ethyl ether (60-29-7))
• Boiling Point: 333.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• PKA: 8.15±0.20(Predicted)
• CAS DataBase Reference: 4-(dimethylamino)-4-phenylcyclohexan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(dimethylamino)-4-phenylcyclohexan-1-one(65619-20-7)
• EPA Substance Registry System: 4-(dimethylamino)-4-phenylcyclohexan-1-one(65619-20-7)

Safety Data

• Hazardous Substances Data: 65619-20-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(dimethylamino)-4-phenylcyclohexan-1-one is utilized as a key precursor in the production of various pharmaceuticals. Its unique structure allows it to be a building block for the creation of diverse medicinal compounds, contributing to the development of new drugs and therapeutic agents.
Used in Organic Compounds Synthesis:
In the realm of organic chemistry, 4-(dimethylamino)-4-phenylcyclohexan-1-one serves as a valuable intermediate for synthesizing a range of organic compounds. Its versatility in chemical reactions makes it an essential component in organic synthesis processes.
Used in Medicinal Research:
4-(dimethylamino)-4-phenylcyclohexan-1-one is employed in medicinal research for exploring its potential biological activities and applications. Its structure may offer insights into the design of new drugs and the understanding of molecular interactions within biological systems.
Used in Chemical Research:
4-(dimethylamino)-4-phenylcyclohexan-1-one is also used in chemical research to study its properties and reactivity. Understanding its behavior in various chemical reactions can lead to the discovery of new synthetic methods and applications in the chemical industry.
It is crucial to handle 4-(dimethylamino)-4-phenylcyclohexan-1-one with care due to its potential health hazards if mismanaged, emphasizing the need for proper safety measures during its use in research and industrial applications.

Upstream product

• 100-58-3 phenylmagnesium bromide 
• 100-59-4 phenylmagnesium chloride 
• 65619-92-3 8-(dimethylamino)-1,4-dioxaspiro-[4.5]-decane-8-carbonitrile 
• 65619-18-3 4-methylamino-4-phenylcyclohexanone, ethylene ketal hydrochloride 
• 591-51-5 phenyllithium 
• 1071066-97-1 N-(1,4-dioxaspiro-[4,5]-decan-8-yliden)-methanamine 
• 79741-33-6 methyl-(8-phenyl-1,4-dioxaspiro[4.5]dec-8-yl)amine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 77253-85-1 dimethyl-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)amine 
• 65618-70-4 4-(p-chlorophenyl)-4-dimethylaminocyclohexanone, ethylene ketal hydrochloride 
• 65619-19-4 4-dimethylamino-4-phenylcyclohexanone, ethylene ketal hydrochloride 

Downstream Products

• 691880-02-1 N,N-dimethyl-N-{4-phenyl-2',3',4',9'-tetrahydrospiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-yl}-amine 
• 1189795-75-2 4-dimethylamino-4-phenyl-1-(pyrrolidin-1-yl)cyclohexane carbonitrile 
• 1189795-74-1 1,4-bis-dimethylamino-4-phenyl-cyclohexane carbonitrile 
• 1189795-76-3 4-dimethylamino-1-methylamino-4-phenyl-cyclohexane carbonitrile 
• 1189795-77-4 [4-methoxy-4-(3-methoxy-prop-1-ynyl)-1-phenyl-cyclohexyl]-dimethylamine 
• 1189795-80-9 N,N-dimethyl-4-methylene-1-phenylcyclohexan-1-amine 
• 1189795-84-3 (4-butylidene-1-phenyl-cyclohexyl)-dimethylamine 
• 1189752-78-0 N,N-dimethyl-4,4-bis(3-methyl-1H-indol-2-yl)-1-phenylcyclohexanamine 
• 1189753-09-0 N,N-dimethyl-1-phenyl-4,4-(bis-(3-(2-pyridin-4-yl)ethyl)-1H-indol-2-yl)cyclohexylamine 
• 1004541-97-2 (+/-)-2-(4-(Dimethylamino)-4-phenylcyclohex-1-enyl)-3-(2-(pyridin-4-yl)ethyl)-1H-indole 
• 1189163-36-7 (+/-)-2-benzyl-4-dimethylamino-4-phenylcyclohexanone 
• 1189163-47-0 (+/-)-3-(5-dimethylamino-2-oxo-5-phenylcyclohexyl)propionitrile 
• 1189163-35-6 (+/-)-4-dimethylamino-2-methyl-4-phenylcyclohexanone 

Relevant articles and documents

4,5-DIHYDRO-1H-THIENO[2,3-G]INDAZOLYL DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES

The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diazaspiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES

The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

Discovery of a potent analgesic NOP and opioid receptor agonist: Cebranopadol

In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacological properties revealed. We herein report our efforts to further optimize lead 2a, toward trans-6′-fluoro-4′, 9′-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1′(3′H) -pyrano[3,4-b]indol]-4-amine (cebranopadol, 3a), which is currently in clinical development for the treatment of severe chronic nociceptive and neuropathic pain.

Discovery of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as potent NOP and opioid receptor agonists

We report the discovery of spiro[cyclohexane-pyrano[3,4-b]indole]-amines, as functional nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonists with strong efficacy in preclinical models of acute and neuropathic pain. Utilizing 4-(dimethylamino)-4-phenylcyclo-hexanone 1 and tryptophol in an oxa-Pictet-Spengler reaction led to the formation of spiroether 2, representing a novel NOP and opioid peptide receptor agonistic chemotype. This finding initially stems from the systematic derivatization of 1, which resulted in alcohols 3-5, ethers 6 and 7, amines 8-10, 22-24, and 26-28, amides 11 and 25, and urea 12, many with low nanomolar binding affinities at the NOP and mu opioid peptide (MOP) receptors.

Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine Compounds

Cis-tetrahydro-spiro(cyclohexane-1,1′-pyrido[3,4-b]indole)-4-amine compounds which act on the nociceptin/ORL-1 receptor system as well as on the μ-opioid receptor system and which are distinguished in particular by selective effectiveness in the treatment of chronic pain, such as inflammatory pain, visceral pain, tumour pain, and neuropathic pain, without at the same time developing pronounced effectiveness against acute, nociceptive pain.